A novel, selective BCR-ABL inhibitor. More potent than imatinib against wild-type BCR-ABL (IC50 < 30 nM). Induces apoptosis
Know who made it. See the evidence. Buy through one marketplace.
A novel, selective BCR-ABL inhibitor. More potent than imatinib against wild-type BCR-ABL (IC50 < 30 nM). Induces apoptosis
This product is manufactured by TriBio Science and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
ABL1 is ABL proto-oncogene 1, non-receptor tyrosine kinase, encoding the c-Abl/tyrosine-protein kinase ABL1 protein. This record links the verified human identity (NCBI Gene 25; UniProt P00519) to ABMIUM catalogue products.
Biological function: ABL1 encodes tyrosine-protein kinase ABL1 (c-Abl), a non-receptor tyrosine kinase involved in cell division, adhesion, differentiation and cellular stress responses. ABL1 is also a recurrent fusion partner in cancer biology, most notably in the BCR::ABL1 fusion context.
